JCO-话题@MedSci

#JCO#

724篇内容 | 6895人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1891649, encodeId=d9d418916492f, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：各类方案治疗的不同分期肾上腺皮质癌患儿的预后, objectType=article, longId=209949, objectId=f19920994976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f19920994976, replyNumber=0, likeNumber=84, createdTime=2022-01-28, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f19920994976, moduleTitle=JCO：各类方案治疗的不同分期肾上腺皮质癌患儿的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f19920994976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, objectType=article, longId=212622, objectId=2be02126223c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be02126223c, replyNumber=0, likeNumber=78, createdTime=2021-11-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be02126223c, moduleTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be02126223c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891645, encodeId=8cf0189164567, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：基因检测对低风险前列腺癌治疗策略选择的影响, objectType=article, longId=209804, objectId=a367209804e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a367209804e0, replyNumber=0, likeNumber=76, createdTime=2021-10-28, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a367209804e0, moduleTitle=JCO：基因检测对低风险前列腺癌治疗策略选择的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a367209804e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891618, encodeId=c731189161804, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：HER2双重靶向治疗显著改善乳腺癌患者预后, objectType=article, longId=202479, objectId=bfbc2024e9d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc2024e9d6, replyNumber=0, likeNumber=65, createdTime=2021-02-20, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc2024e9d6, moduleTitle=JCO：HER2双重靶向治疗显著改善乳腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfbc2024e9d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891633, encodeId=6b1c18916336c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：化疗加上原发性肿瘤切除并不能提升晚期结直肠癌患者的疗效, objectType=article, longId=207044, objectId=158c20e0442d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=158c20e0442d, replyNumber=0, likeNumber=79, createdTime=2021-08-25, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=158c20e0442d, moduleTitle=JCO：化疗加上原发性肿瘤切除并不能提升晚期结直肠癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=158c20e0442d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891653, encodeId=63e418916533d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, objectType=article, longId=211042, objectId=63df21104261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df21104261, replyNumber=0, likeNumber=78, createdTime=2021-10-21, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df21104261, moduleTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df21104261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891676, encodeId=3f9318916e634, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：易感基因突变携带者患乳腺癌的风险有多大？新方法给出答案, objectType=article, longId=213149, objectId=9fae21314903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fae21314903, replyNumber=0, likeNumber=59, createdTime=2021-08-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fae21314903, moduleTitle=JCO：易感基因突变携带者患乳腺癌的风险有多大？新方法给出答案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fae21314903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891626, encodeId=9d18189162699, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO: 纳武利尤单抗治疗晚期NSCLC五年生存率可达化疗的5倍！, objectType=article, longId=205955, objectId=9ddd2059556a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ddd2059556a, replyNumber=0, likeNumber=83, createdTime=2021-09-19, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ddd2059556a, moduleTitle=JCO: 纳武利尤单抗治疗晚期NSCLC五年生存率可达化疗的5倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ddd2059556a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891662, encodeId=77c2189166219, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：预测接受胸部放疗过的儿童癌症幸存者患乳腺癌风险的预测模型, objectType=article, longId=212162, objectId=8c8c212162d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c8c212162d5, replyNumber=0, likeNumber=90, createdTime=2022-01-10, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c8c212162d5, moduleTitle=JCO：预测接受胸部放疗过的儿童癌症幸存者患乳腺癌风险的预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c8c212162d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891654, encodeId=363b189165463, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性, objectType=article, longId=211096, objectId=5efc211096c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5efc211096c3, replyNumber=0, likeNumber=68, createdTime=2021-11-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5efc211096c3, moduleTitle=JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5efc211096c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891634, encodeId=d0ff18916346c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, objectType=article, longId=207552, objectId=b86b20e552cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86b20e552cf, replyNumber=0, likeNumber=83, createdTime=2021-08-29, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86b20e552cf, moduleTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86b20e552cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891650, encodeId=23391891650a2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！, objectType=article, longId=210240, objectId=c7a6210240c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a6210240c2, replyNumber=0, likeNumber=86, createdTime=2021-04-20, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a6210240c2, moduleTitle=JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a6210240c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891652, encodeId=8a8c1891652a1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO: 对错配修复基因缺陷的人群进行监测管理可带来生存获益, objectType=article, longId=211022, objectId=e5e4211022c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e4211022c9, replyNumber=0, likeNumber=56, createdTime=2022-03-31, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e4211022c9, moduleTitle=JCO: 对错配修复基因缺陷的人群进行监测管理可带来生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5e4211022c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891637, encodeId=d415189163e61, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Tipifarnib对复发和/或转移性头颈鳞癌疗效显著, objectType=article, longId=208966, objectId=e02220896609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e02220896609, replyNumber=0, likeNumber=70, createdTime=2021-04-10, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e02220896609, moduleTitle=JCO：Tipifarnib对复发和/或转移性头颈鳞癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e02220896609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891642, encodeId=dc7c1891642b4, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好, objectType=article, longId=209307, objectId=690420930ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690420930ed9, replyNumber=0, likeNumber=77, createdTime=2021-10-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690420930ed9, moduleTitle=JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=690420930ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891628, encodeId=f1971891628a3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：特瑞普利单抗治疗鼻咽癌患者带来更长生存获益, objectType=article, longId=206306, objectId=4f9e2063068a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f9e2063068a, replyNumber=0, likeNumber=233, createdTime=2022-01-03, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f9e2063068a, moduleTitle=JCO：特瑞普利单抗治疗鼻咽癌患者带来更长生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f9e2063068a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891625, encodeId=cef51891625a4, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见, objectType=article, longId=205799, objectId=475b205e990c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475b205e990c, replyNumber=0, likeNumber=103, createdTime=2021-08-28, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475b205e990c, moduleTitle=JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475b205e990c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891630, encodeId=fee318916306a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, objectType=article, longId=206737, objectId=4e1b206e376a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1b206e376a, replyNumber=0, likeNumber=82, createdTime=2021-08-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1b206e376a, moduleTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1b206e376a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891635, encodeId=6d1b189163597, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, objectType=article, longId=207818, objectId=f15320e81875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15320e81875, replyNumber=0, likeNumber=67, createdTime=2021-03-11, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15320e81875, moduleTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f15320e81875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891616, encodeId=71b61891616f5, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：CheckMate 066试验| 纳武单抗治疗晚期黑色素瘤的5年随访结果, objectType=article, longId=201677, objectId=01c02016e7b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c02016e7b3, replyNumber=0, likeNumber=66, createdTime=2021-07-21, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c02016e7b3, moduleTitle=JCO：CheckMate 066试验| 纳武单抗治疗晚期黑色素瘤的5年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01c02016e7b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JCO

2020-05-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：各类方案治疗的不同分期肾上腺皮质癌患儿的预后

2022-01-28

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析

2021-11-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：基因检测对低风险前列腺癌治疗策略选择的影响

2021-10-28

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：HER2双重靶向治疗显著改善乳腺癌患者预后

2021-02-20

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：化疗加上原发性肿瘤切除并不能提升晚期结直肠癌患者的疗效

2021-08-25

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性

2021-10-21

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：易感基因突变携带者患乳腺癌的风险有多大？新方法给出答案

2021-08-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO: 纳武利尤单抗治疗晚期NSCLC五年生存率可达化疗的5倍！

2021-09-19

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：预测接受胸部放疗过的儿童癌症幸存者患乳腺癌风险的预测模型

2022-01-10

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性

2021-11-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS

2021-08-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！

2021-04-20

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO: 对错配修复基因缺陷的人群进行监测管理可带来生存获益

2022-03-31

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Tipifarnib对复发和/或转移性头颈鳞癌疗效显著

2021-04-10

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好

2021-10-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：特瑞普利单抗治疗鼻咽癌患者带来更长生存获益

2022-01-03

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见

2021-08-28

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％

2021-08-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%

2021-03-11

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：CheckMate 066试验| 纳武单抗治疗晚期黑色素瘤的5年随访结果

2021-07-21

科室
- - 订阅+
  - 更多科室
工具
服务